Table 2. Cost-effectiveness of CMV vaccination strategies.

Vaccination strategy	Cost (million US$)	DALY	ICER (US$/DALY averted) versus status quo	ICER (US$/DALY averted) versus next best
No vaccination	4 26 696 (4 25 979–4 27 414)	9 346 456	–	–
		(9 328 596–9 364 316)
pre-marriage vaccination	435 686	7 371 399	4751	4751
	(4 34 777–4 36 596)	(7 356 764–7 386 033)	(4124–5378)	(4124–5378)
Reproductive-age vaccination	457 021	6 549 424	10 814	25 553
	(4 54 882–4 57 470)	(6 536 887–6 561 960)	(10 290–11 338)	(12 566–36 126)

Costs and DALYs were discounted at 3%. Data are presented as medium and 95% uncertainty interval (Ul).

cCMV, congenital cytomegalovirus; CMV, cytomegalovirus; DALY, disability-adjusted life year; ICER, incremental cost-effectiveness ratio.